The US FDA's Office of Prescription Drug Promotion (OPDP) found few objectionable drug promotions in 2018, issuing only seven letters in what seems to be another year of the agency reassessing its approach to Rx communications rather than making a public push on any enforcement priorities.
OPDP's tally was just two more than the record low of five sent in 2017. An additional untitled letter was issued by the Center for Biologics Evaluation and Research's Advertising...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?